GLP-1 Insurance Coverage: What Wegovy, Zepbound, Ozempic, and Mounjaro Actually Cost You

Why Insurance Coverage Differs Across GLP-1 Drugs

The FDA approval indication on a drug's label determines coverage more than the molecule itself. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) and Mounjaro (tirzepatide 2.5 mg to 15 mg) are approved for type 2 diabetes management, placing them in a medication class that nearly every commercial plan and Medicare Part D formulary covers. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 2.5 mg to 15 mg) carry obesity indications, and coverage there is far patchier.

Historically, most insurers treated obesity as a lifestyle issue rather than a chronic disease, so weight-loss drugs were excluded from the majority of formularies. That view is shifting, but slowly. The American Association of Clinical Endocrinology's 2016 obesity guidelines explicitly classify obesity as a chronic, relapsing neuroendocrine disease requiring medical intervention [1], yet payer policy still lags behind the clinical evidence.

The practical consequence: a patient with type 2 diabetes can get semaglutide covered under the Ozempic label, while the same molecule dosed at 2.4 mg under the Wegovy label for obesity may face a flat denial. Same active ingredient, two very different coverage outcomes.

Active ingredient equivalences worth knowing:

• Semaglutide: Ozempic (diabetes, injection), Wegovy (obesity, injection), Rybelsus (diabetes, oral tablet)
• Tirzepatide: Mounjaro (diabetes, injection), Zepbound (obesity, injection)

Wegovy Cost: List Price, Insurance, and Savings Programs

Wegovy's US wholesale acquisition cost sits at $1,349.02 per 28-day supply as of 2024 [2]. That number assumes no insurance, no coupon, and no manufacturer savings. Few patients pay that full amount, but many pay more than they expect.

Commercial insurance. Plans that cover Wegovy typically require prior authorization. Standard criteria mirror the FDA label for semaglutide 2.4 mg [2]: a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease), plus documented failure of lifestyle interventions. Some plans add a requirement for a 5% weight-loss response at 16 weeks before continuing coverage.

Medicare. Medicare Part D plans historically excluded weight-loss medications. The Inflation Reduction Act and subsequent CMS rulemaking opened a pathway for Medicare Part D plans to optionally cover anti-obesity medications starting in 2025, citing the SELECT trial as a driver. SELECT (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a median 34 months in patients with overweight or obesity and established cardiovascular disease, with no diabetes diagnosis [3]. That cardiovascular benefit data shifted the regulatory and payer conversation.

Novo Nordisk savings card. Commercially insured patients who qualify may pay as low as $0 per month through the NovoCare savings program. Patients without any insurance coverage can access Novo Nordisk's direct cash-pay pricing starting at $149 per month for lower maintenance doses through the company's own pharmacy program, though this applies to specific doses and may not reflect titration needs.

STEP-1 (N=1,961) established the efficacy basis for these approvals: semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [4]. The two-year STEP-5 data extended that finding, showing sustained 15.2% weight loss at 104 weeks [5].

Zepbound Cost: List Price, Insurance, and Savings Programs

Zepbound's list price is $1,086.37 per 28-day supply [6]. That makes it nominally cheaper than Wegovy at list, though the dose taken and titration schedule affect actual monthly spend.

Commercial insurance. Coverage criteria for Zepbound generally mirror Wegovy's: BMI 30 or higher, or BMI 27 or higher with a qualifying comorbidity, with prior authorization required. Eli Lilly's Zepbound FDA label [6] specifies the same inclusion criteria. Some payers add step-therapy requirements, demanding documented trials of other weight-loss agents first.

Eli Lilly savings card. Through the Lilly Savings Card, commercially insured patients may pay as little as $25 per month. Lilly also offers Zepbound vials through LillyDirect at reduced cash-pay prices ($399 for 2.5 mg and 5 mg vials, $549 for 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials per month as of late 2024), which is considerably below the branded autoinjector list price.

The efficacy justifying coverage requests is substantial. SURMOUNT-1 (N=2,539) found that tirzepatide 15 mg produced a 22.5% mean reduction in body weight at 72 weeks versus 2.4% with placebo (P<0.001) [7]. SURMOUNT-3 (N=806) showed that patients who completed an intensive lifestyle intervention and then received tirzepatide achieved an additional 18.4% weight reduction at 72 weeks [8]. SURMOUNT-4 (N=783) demonstrated that patients who stopped tirzepatide regained 14% of body weight over 88 weeks versus continued weight loss with ongoing treatment, making a strong case for long-term coverage rather than short-term authorizations [9].

Ozempic Cost: List Price, Insurance, and Coverage Reality

Ozempic's list price runs approximately $980 per 28-day supply. Because it carries a type 2 diabetes indication, the coverage picture is meaningfully better than for its obesity-labeled peers.

Commercial and employer plans. Most formularies place Ozempic on a mid-tier preferred brand level. Out-of-pocket costs after a deductible commonly land between $25 and $150 per month for insured patients, though this varies enormously by plan design.

Medicare Part D. Ozempic appears on many Part D formularies as a diabetes medication. The 2025 Medicare drug price negotiation under the Inflation Reduction Act designated semaglutide products for negotiation, which may affect formulary placement in upcoming plan years.

Off-label weight loss prescribing. Physicians prescribe Ozempic off-label for obesity at doses up to 1 mg or 2 mg. Coverage for that use is inconsistent. Insurers who discover the primary diagnosis is obesity rather than diabetes sometimes deny or claw back claims. Patients should confirm whether their specific diagnosis justifies the prescription before assuming coverage applies.

STEP-2 (N=1,210) confirmed semaglutide 1 mg's efficacy in type 2 diabetes: 9.6% body weight reduction at 68 weeks versus 3.4% with placebo (P<0.001), alongside HbA1c reductions of 2.2 percentage points [10]. This diabetes efficacy data underpins the formulary placements Ozempic currently enjoys.

Mounjaro Cost: List Price, Insurance, and Coverage Reality

Mounjaro's list price is $1,079.77 per 28-day supply. Like Ozempic, its diabetes indication gives it a substantial insurance advantage over the weight-focused tirzepatide product (Zepbound).

Commercial insurance. Most major commercial plans cover Mounjaro for type 2 diabetes, typically requiring a confirmed diagnosis, documentation that first-line agents (metformin, sulfonylureas) were inadequate or not tolerated, and prior authorization. Some plans require the prescriber to confirm the patient is not using Mounjaro solely for weight loss.

Medicare Part D. Medicare covers Mounjaro for type 2 diabetes across most Part D formularies. Coverage for weight management alone remains excluded unless the plan has opted into the new anti-obesity medication benefit.

Lilly savings card. The Lilly Savings Card offers commercially insured patients a co-pay as low as $25 per month. Patients without commercial insurance do not qualify for this card, but Lilly maintains a patient assistance program for those below income thresholds.

SURMOUNT-2 (N=938) studied tirzepatide specifically in patients with type 2 diabetes and obesity: tirzepatide 15 mg produced 15.7% weight loss at 72 weeks versus 3.3% with placebo (P<0.001), alongside meaningful HbA1c reductions [11]. This dual metabolic benefit (glycemic control plus weight reduction) is part of what makes prescribers and payers view tirzepatide as differentiated.

How Prior Authorization Actually Works

Prior authorization (PA) is the single largest administrative barrier between a patient and a filled GLP-1 prescription. Understanding the process reduces denial rates.

A standard PA submission for any of these four drugs needs:

1. The confirmed diagnosis code (E11.x for type 2 diabetes, E66.x for obesity, or the specific comorbidity code if BMI is 27 to 29.9).
2. Current height, weight, and calculated BMI.
3. Documentation of prior treatments tried, failed, or contraindicated.
4. A letter of medical necessity from the prescriber.
5. For obesity indications: evidence that intensive behavioral interventions were attempted (meeting frequency, duration, and content per CMS criteria or insurer requirements).

Denials most commonly cite "not meeting BMI threshold," "insufficient documentation of prior therapy," or "obesity not a covered condition." All three are appellable. A prescriber's letter directly quoting the SELECT trial's cardiovascular outcomes data [3] may be persuasive when appealing a Wegovy denial for a patient with cardiovascular disease, because the trial's 20% MACE reduction gives insurers a medical loss ratio argument for coverage.

The HealthRX GLP-1 Coverage Decision Framework (for prescriber use):

| Step | Action | If Denied | |------|--------|-----------| | 1 | Confirm indication matches the prescribed brand | Switch to diabetes-labeled drug if patient has T2D | | 2 | Verify PA criteria are fully documented before submission | Request peer-to-peer review within 7 days | | 3 | Submit PA with BMI, diagnosis, prior therapy documentation | Appeal with SELECT or SURMOUNT trial citations | | 4 | Check savings card eligibility (Lilly: $25/mo, Novo: $0/mo) | Apply for manufacturer patient assistance if uninsured | | 5 | Explore LillyDirect vials or Novo cash-pay program | Consider compounded semaglutide only while FDA shortage listing active |

Medicare and Medicaid: The Evolving Coverage Picture

Medicare's historical exclusion of anti-obesity medications stemmed from a 2003 National Coverage Determination that classified obesity drugs as lifestyle medications. That policy is being revised.

Under the Inflation Reduction Act, CMS issued guidance allowing (but not requiring) Medicare Part D plans to cover anti-obesity medications approved after April 1, 2013, starting in 2025. Wegovy and Zepbound both meet that date threshold. Plans electing to cover them may do so, but enrollment in a plan that includes the benefit is not guaranteed.

Medicaid coverage varies by state. As of early 2025, approximately 13 states cover at least one anti-obesity GLP-1 under Medicaid with prior authorization. Patients in other states may still access coverage for the diabetes-labeled versions if they carry a type 2 diabetes diagnosis.

The broader Medicaid picture matters because the prevalence of obesity disproportionately affects lower-income populations. CDC data shows that obesity prevalence among adults living below the federal poverty level reaches approximately 36%, compared with 29% among those with higher incomes [12]. A payer system that restricts access based on plan type structurally limits access for the population with the highest disease burden.

Comparing Out-of-Pocket Costs Across Four Scenarios

The actual amount a patient pays depends on the intersection of insurance type, diagnosis, savings card eligibility, and pharmacy choice.

Scenario A: Commercially insured, type 2 diabetes diagnosis. Ozempic or Mounjaro, mid-tier formulary. Expected co-pay: $25 to $100 per month after deductible. Lilly savings card reduces Mounjaro to $25. Novo savings card may reduce Ozempic similarly.

Scenario B: Commercially insured, obesity diagnosis only. Wegovy or Zepbound, if covered. Expected co-pay with savings card: $0 to $25 per month. If not covered: $1,086 to $1,349 at list price without any assistance.

Scenario C: Medicare Part D, type 2 diabetes. Ozempic or Mounjaro on formulary. After the 2025 $2,000 out-of-pocket cap under the IRA, maximum annual exposure is capped regardless of drug price. Monthly cost varies by plan but could be $0 to $100 for most of the year.

Scenario D: Uninsured or underinsured. Zepbound vials through LillyDirect: $399 to $549 per month. Novo Nordisk cash-pay Wegovy program: starting at $149 per month for lower doses. GoodRx coupons on Ozempic: approximately $800 to $900 at major chain pharmacies, varying by location.

What to Do If You Are Denied Coverage

Denial is not the end. Insurance companies deny approximately 17% of in-network claims across all categories, and GLP-1 denial rates run higher. The appeals process has a meaningful success rate when approached systematically.

Step 1: Understand the denial reason. The Explanation of Benefits (EOB) must specify the reason. "Not medically necessary" requires a different appeal than "not a covered benefit."

Step 2: Request a peer-to-peer review. The prescriber calls the insurer's medical director directly. This single step reverses denials in a meaningful share of cases, particularly when the prescriber can cite trial data. The AACE guidelines [1] describing obesity as a chronic neuroendocrine condition, combined with SELECT's cardiovascular mortality data [3], provide clinically grounded arguments.

Step 3: File a formal written appeal. Include the full PA documentation, the prescriber's letter of medical necessity, relevant trial citations, and any specialist letters. Most plans allow up to three levels of internal appeal.

Step 4: Request an external independent review. All ACA-compliant plans must offer external review by an independent organization. External reviewers reverse insurer denials at rates that vary by state but can reach 40% for certain drug categories.

Step 5: Contact the manufacturer. Both Eli Lilly and Novo Nordisk have patient access teams that can sometimes support appeals or provide bridge supply during the appeals process.

Compounded Semaglutide and Tirzepatide: A Cost Note

While branded GLP-1s remained on the FDA drug shortage list, compounding pharmacies legally produced semaglutide and tirzepatide. FDA removed semaglutide from the shortage list in March 2025, triggering enforcement action against most compounders. Tirzepatide's shortage status is under ongoing review.

Compounded versions are not FDA-approved, carry no bioequivalence data, and are not covered by insurance. They have appeared at prices of $150 to $300 per month, which is their primary appeal. The FDA has issued warning letters to multiple outsourcing facilities for quality violations. Prescribers considering compounded options should document patient counseling about these risks. The agency's updated guidance on this topic is available at FDA.gov [13].

The Cardiovascular Case for Broader Coverage

Insurers increasingly respond to cardiovascular outcome data because it directly affects medical loss ratios. The SELECT trial enrolled 17,604 patients with overweight or obesity (BMI 27 or higher) and established cardiovascular disease but no diabetes. Over a median of 34.2 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% versus placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [3].

"Semaglutide reduced the risk of serious cardiovascular events in patients with obesity who did not have diabetes," stated the SELECT trial investigators, providing the first prospective RCT evidence that an anti-obesity agent reduces hard cardiovascular endpoints [3]. That sentence, embedded in an NEJM publication, represents the data point that shifted several large self-insured employers to add GLP-1 obesity coverage in 2024.

The STEP-8 trial (N=338) compared semaglutide 2.4 mg directly against liraglutide 3 mg: semaglutide produced 15.8% weight loss at 68 weeks versus 6.4% with liraglutide (P<0.001), with a favorable side-effect profile [14]. Head-to-head superiority data helps formulary committees justify tiered pricing and coverage decisions.

Employer-Sponsored Plans: A Faster-Moving Coverage Frontier

Commercial insurers move slowly. Large self-insured employers move faster, because they bear the direct cost of their employees' health claims. Approximately 42% of large employers (500 or more employees) covered at least one GLP-1 for obesity in 2024, up from 25% in 2022, according to benefit consulting surveys.

Employer plans can add GLP-1 obesity coverage mid-year through plan amendments. Employees whose employers have not yet added coverage can request that HR departments review the cost-benefit modeling, which typically shows that preventing downstream bariatric surgery, cardiovascular events, and diabetes-related hospitalizations offsets a substantial portion of the drug cost. A prescriber letter to an employer's benefits team, citing SELECT and SURMOUNT trial data, has prompted coverage additions at several mid-sized companies based on HealthRX prescriber reports.